Encodes An Enzyme Patents (Class 536/23.2)
  • Patent number: 11920174
    Abstract: The present invention relates to analysis of an RNA molecule. It further relates to the use of this method for the quality control of an RNA molecule produced by in vitro transcription or for the quality control of an RNA molecule produced by chemical synthesis.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 5, 2024
    Assignee: CureVac SE
    Inventors: Fabian Johannes Eber, Aniela Wochner, Tilmann Roos
  • Patent number: 11773407
    Abstract: Aspects of the disclosure relate to synthetic regulatory systems composed of a multifunctional Cas nuclease, at least two guide RNAs (gRNAs) configured to target distinct nucleotide sequences, and a multilayered regulatory control element comprising ribozyme-based safety switches providing spatial and temporal control over the synthetic circuit in vivo.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: October 3, 2023
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Samira Kiani, Mo Reza Ebrahimkhani, Swechchha Pradhan, Farzaneh Moghadam
  • Patent number: 11713451
    Abstract: The present disclosure relates to engineered ketoreductase polypeptides for the preparation of hydroxyl substituted carbamate compounds, and polynucleotides, vectors, host cells, and methods of making and using the ketoreductase polypeptides.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 1, 2023
    Assignee: Codexis, Inc.
    Inventors: Fabien Louis Cabirol, Haibin Chen, Anupam Gohel, Steven J. Collier, Derek J. Smith, Birgit Kosjek, Jacob Janey
  • Patent number: 11708389
    Abstract: Disclosed here are compositions of matter that comprise DNA analogues that have been rectified by replacing the four standard components with alternative components that mitigate various problems frequently encountered during synthesis of these compounds, during the functioning of these compounds, and complex mixtures for information data storage.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: July 25, 2023
    Inventor: Steven Benner
  • Patent number: 11534463
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: December 27, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone
  • Patent number: 11485959
    Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: November 1, 2022
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric M. Ostertag, Blair Madison
  • Patent number: 11447782
    Abstract: The instant disclosure is generally related to novel engineered (hybrid) promoters. In certain embodiments, the instant disclosure is directed to one or more nucleic acid compositions comprising engineered promoters operably linked to nucleic acids encoding proteins of interest. Thus, the disclosure set forth herein described methods and compositions for the production of proteins of interest using one or more novel engineered (hybrid) promoters of the disclosure.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: September 20, 2022
    Assignee: DANISCO US INC.
    Inventors: Cristina Bongiorni, Marc Kolkman, Chris Leeflang, Virgil Arthur Rhodius, Anita Van Kimmenade
  • Patent number: 11414670
    Abstract: The present disclosure provides compositions and methods for altering gibberellin (GA) content in corn or other cereal plants. Methods and compositions are also provided for altering the expression of genes related to gibberellin biosynthesis through suppression, mutagenesis and/or editing of specific subtypes of GA20 or GA3 oxidase genes. Modified plant cells and plants having a suppression element or mutation reducing the expression or activity of a GA oxidase gene are further provided comprising reduced gibberellin levels and improved characteristics, such as reduced plant height and increased lodging resistance, but without off-types.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: August 16, 2022
    Assignee: Monsanto Technology LLC
    Inventors: Edwards M. Allen, Jayanand Boddu, Charles R. Dietrich, Alexander Goldshmidt, Miya Howell, Kevin R. Kosola, Anil Neelam, Thomas L. Slewinski, Tyamagondlu V. Venkatesh, Huai Wang, Sivalinganna Manjunath, Linda Rymarquis
  • Patent number: 11274138
    Abstract: The invention relates to identification and characterization of recombinant DNA and polypeptides for specific Bt toxin receptors. In particular, the Bt toxin receptors of the invention include those derived from the Lepidopteran super family including the species Trichoplusiani ni, Pseudoplusia includens, Helicoverpa zea, and Spodoptera frugiperda. The receptors of the invention further include those derived from the Coleopteran super family and particularly from the species Diabrotica virgifera virgifera. The recombinant DNA and polypeptides so provided are useful in the identification and design of novel Bt toxin receptor ligands including novel or improved insecticidal toxins for use in a variety of agricultural applications. Materials and methods for identifying novel toxins are also disclosed herein. The invention also provides methods for selecting toxins to combine to control insect populations by manipulating Bt toxin receptor.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 15, 2022
    Assignee: Monsanto Technology LLC
    Inventors: Edward Kraft, Renata Bolognesi, Artem Evdokimov, Farhad Moshiri, Meiying Zheng, Victor M. Guzov
  • Patent number: 11254699
    Abstract: The present application relates to methods for the production of plant material suitable for the extraction and purification of saponins, through plantations of clone plants of defined chemotype, including ultrahigh density plantations of Quillaja saponaria Molina, and methods to increase the recovery of saponins by solid/liquid extraction of the harvested plant material.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 22, 2022
    Assignee: DESERT KING CHILE S.A.
    Inventors: Leandro Padilla Iglesias, Javier Gonzalez Castro, Rodrigo Otero Peredo
  • Patent number: 11186831
    Abstract: Provided is a mutant PHA synthase which produces of a PHA copolymer with a high or low 3HH ratio while maintaining PHA productivity. The mutant PHA synthase is a mutant polyhydroxyalkanoate synthase having an amino acid sequence having 85% or more sequence identity with the amino acid sequence of SEQ ID NO: 1 and having at least one of the following mutations (a) to (c): (a) a substitution of serine at 389th position from N-terminus of the amino acid sequence of SEQ ID NO: 1 with an amino acid other than serine; (b) a substitution of leucine at 436th position from the N-terminus of the amino acid sequence of SEQ ID NO: 1 with an amino acid other than leucine; and (c) a deletion of 11 to 19 amino acid residues from the C-terminus of the amino acid sequence of SEQ ID NO: 1.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: November 30, 2021
    Assignee: KANEKA CORPORATION
    Inventors: Shingo Kobayashi, Shinichi Yoshida, Shunsuke Sato, Naoaki Taoka
  • Patent number: 11130960
    Abstract: Provided are methods for conferring and/or enhancing herbicide resistance on plants or algae including agricultural crops by introducing prokaryote-derived protoporphyrinogen oxidase variants.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: September 28, 2021
    Assignee: FARM HANNONG CO., LTD.
    Inventors: Soon-Kee Sung, Joonseon Yoon, Yunjung Han
  • Patent number: 11098315
    Abstract: The present invention relates to the production of steviol glycoside rebaudiosides D4, WB1 and WB2 and the production of rebaudioside M from Reb D4.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: August 24, 2021
    Assignee: Conagen Inc.
    Inventors: Guohong Mao, Jacob Edward Vick, Michael Batten, Yang Luo, Yilin Wu, Beihua Zhang, David Byun, Xiaodan Yu
  • Patent number: 10947507
    Abstract: Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: March 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Richard Klemke, Huawei Wang
  • Patent number: 10857388
    Abstract: A method of treating cancer includes administering a first dose of radiation to a subject; determining a level of a biomarker obtained from the subject, the level indicating an immune response of the subject to the first dose; and not administering a second dose of radiation to the subject unless and until the level of the biomarker is beyond a threshold value.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 8, 2020
    Inventors: Frank Giordano, Matthias Benker, Matthias Ahlgrimm
  • Patent number: 10844362
    Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: November 24, 2020
    Assignee: President and Fellows of Harvard
    Inventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
  • Patent number: 10801032
    Abstract: This disclosure relates to the field of plant molecular biology; more particularly to the field of agriculture; even more particularly to the field of improving the yield of plants. This disclosure provides chimeric genes and constructs that can be used to enhance the yield in plants and crops.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 13, 2020
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Dirk Gustaaf Inzé, Hannes Claeys, Hilde Nelissen, Xiaohuan Sun
  • Patent number: 10792358
    Abstract: Disclosed herein is a vaccine comprising an antigen and ISG15. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 6, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David Weiner, Daniel Villarreal
  • Patent number: 10787688
    Abstract: The invention provides a process for the preparation of hydrocarbons substituted with at least one group containing at least one oxygen atom, comprising the process steps A) reaction of a carbon source comprising at least one selected from CO2 and CO to give acetate and/or ethanol with a first microorganism, B) separating off of the acetate from the first microorganism, C) reaction of the acetate to give a hydrocarbon substituted with at least one group containing at least one oxygen atom with a second microorganism and optionally D) purification of the hydrocarbon substituted with at least one group containing at least one oxygen atom.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: September 29, 2020
    Assignee: Evonik Operations GmbH
    Inventors: Thomas Haas, Eva Maria Wittmann
  • Patent number: 10744155
    Abstract: The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: August 18, 2020
    Assignee: UNIVERSITETET I OSLO
    Inventors: Maria Vistnes, Geir Christensen, Magnus Aronsen, Ida Gjervold Lunde, Ivar Sjaastad, Cathrine Rein Carlson
  • Patent number: 10716833
    Abstract: The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Manfred Schuster, Hans Loibner, Evelyne Janzek-Hawlat, Bernhard Peball, Stefan Stranner, Bettina Wagner, Robert Weik
  • Patent number: 10443078
    Abstract: The present invention relates to: a novel Pichia kudriavzevii microorganism NG7 showing heat resistance and acid resistance; a composition, for producing organic acid or alcohol, which comprises the microorganism and a culture of the same; and a method, for producing an organic acid or alcohol, which comprises culturing the microorganism.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: October 15, 2019
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Jung Hoon Sohn, Hyun Joo Park, Sun Hee Lee, Jung Hoon Bae, Bong Hyun Sung
  • Patent number: 10344289
    Abstract: The present disclosure relates to engineered zinc finger proteins that target 5-enolpyruvyl shikimate-3-phosphate synthase (EPSPS) genes in plants and methods of using such zinc finger proteins in modulating gene expression, gene inactivation, and targeted gene modification. In particular, the disclosure pertains to zinc finger nucleases for targeted cleavage and alteration of EPSPS genes.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 9, 2019
    Assignees: Dow AgroSciences LLC, Sangamo Therapeutics, Inc.
    Inventors: Manju Gupta, Asha M. Palta, Stephen Novak, Fyodor Urnov, Sunita Gopalan
  • Patent number: 10273496
    Abstract: Plants are provided with increased ribulose-1,5-bisphosphate (RuBP) regeneration capacity during the Calvin cycle through increased expression of sedoheptulose 1,7 bisphosphatase, in combination with reduced photo-respiratory losses through expression of glycolate catabolizing enzymes. Such plants have a greater growth rate and/or improved biomass and/or increased carbon fixation compared to untreated plants, or plants comprising only one of the features above.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: April 30, 2019
    Assignee: BASF SE
    Inventors: Christoph Peterhaensel, Jeroen Van Rie, Claus Frohberg
  • Patent number: 10260101
    Abstract: The present invention provides methods of detecting c-KIT-dependent-melanoma for diagnostic and prognostic purposes. The invention further provides methods of treating such melanoma by inhibiting c-KIT.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 16, 2019
    Assignee: The Regents of the University of California
    Inventors: Boris C. Bastian, John A. Curtin
  • Patent number: 10221424
    Abstract: The present invention provides compositions and methods for regulating expression of heterologous nucleotide sequences in a plant. Compositions include a novel nucleotide sequence for a promoter for the gene encoding Sorghum bicolor TIP2-3. A method for expressing a heterologous nucleotide sequence in a plant using the promoter sequences disclosed herein is provided. The method comprises transforming a plant or plant cell with a nucleotide sequence operably linked to one of the promoters of the present invention.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 5, 2019
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Andrew Carl Crow, Scott Henry Diehn, Brooke Douglas Peterson-Burch
  • Patent number: 10190110
    Abstract: Disclosed herein are botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain 1, V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; or combinations thereof. Specific combination mutations include E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, or E1191Q and S1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: January 29, 2019
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Min Dong, Lisheng Peng, Pål Erik Gustav Stenmark, Ronnie Per Arne Berntsson
  • Patent number: 10100290
    Abstract: An isolated glycosyltransferase (GT) polypeptide capable of: (I): conjugating glucose to flavokermesic acid (FK); and/or (II): conjugating glucose to kermesic acid (KA) and use of this GT to e.g. make Carminic acid.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 16, 2018
    Assignees: Københavns Universitet, Danmarks Tekniske Universitet
    Inventors: Rubini Maya Kannangara, Mads Bennedsen, Bjørn Madsen, Kim Binderup, Ulf Thrane, Rasmus John Normand Frandsen, Uffe Hasbro Mortensen, Birger Lindberg Møller, Finn Thyge Okkels
  • Patent number: 10035983
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: July 31, 2018
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Patent number: 9931387
    Abstract: The present invention provides a nucleic acid, or an immunogenic composition thereof, that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. The present invention also provides methods for triggering an immune response in a cat and methods for treating or preventing a tumor in a cat using the immunogenic composition of the invention.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 3, 2018
    Assignee: INVECTYS
    Inventors: Pierre Langlade Demoyen, Simon Wain-Hobson, Christelle Liard
  • Patent number: 9926354
    Abstract: The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and HIV associated neurocognitive impairment.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: March 27, 2018
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jun Tan, Brian Nelson Giunta, Song Li, Huayan Hou, Paul R. Sanberg
  • Patent number: 9861117
    Abstract: The invention is directed to an animal feed suitable for feeding mammals, birds and fish, comprising an alkyl ester of a fatty acid, wherein said fatty acid has a chain length of 5-12 carbon atoms, and wherein the dosage of said ester in said animal feed is 50 ppm by weight or higher, based on the total weight of said animal feed.
    Type: Grant
    Filed: January 25, 2010
    Date of Patent: January 9, 2018
    Assignee: Nutreco Nederland B.V.
    Inventors: Yanming Han, Coenraad Henricus Maria Smits, John Brennan, Gregory Ian Page, Johannes Teunis Pieter Van Dam
  • Patent number: 9790252
    Abstract: Disclosed are halogenated 2-deoxy-lactone, 2?-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: October 17, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony A. Sauve, Yana Cen
  • Patent number: 9777282
    Abstract: A microorganism of the genus Corynebacterium with an improved ability to produce L-lysine in which a septum formation initiator protein is inactivated and a method for producing L-lysine using the microorganism.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 3, 2017
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Jun Ok Moon, Sang Hee Park, Lan Huh, Kwang Ho Lee
  • Patent number: 9758831
    Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: September 12, 2017
    Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Michael Gurevich
  • Patent number: 9738877
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: August 22, 2017
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Fred Reichert, Shawn Suko
  • Patent number: 9624500
    Abstract: The invention provides methods and compositions for modifying tocochromanol biosynthesis in plants. The present invention thus surprisingly and beneficially provides for increasing desired tocochromanol compounds in plants and enhancing the nutritional quality of human food and animal feed, without associate deleterious plant phenotypes.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: April 18, 2017
    Assignee: The Curators of the University of Missouri
    Inventors: Gary Stacey, Minviluz G. Stacey
  • Patent number: 9597391
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: March 21, 2017
    Assignee: HELMHOLTZ_ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Patent number: 9593148
    Abstract: The present invention relates to non-competitive allosteric peptide inhibitors of DPP9 and/or DPP8, competitive peptides binding to SUMO1, nucleic acid molecules and expression vectors coding said peptide inhibitors, host cells expressing said inhibitors, kits comprising said inhibitors, as well as methods of producing said inhibitors, and uses of said peptide inhibitors; as further defined in the Claims.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 14, 2017
    Assignee: GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS
    Inventors: Ruth Geiss-Friedlander, Esther Pilla
  • Patent number: 9573982
    Abstract: The present invention provides modified tamabidin 2, which is a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2, an amino acid sequence having one or more amino acid mutations in the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having an identity of not less than 80% to the amino acid sequence of SEQ ID NO: 2 and having biotin-binding activity, wherein an asparagine residue at position 115 of SEQ ID NO: 2 is replaced with cysteine. The modified biotin-binding protein has remarkable heat resistance.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: February 21, 2017
    Assignee: JAPAN TOBACCO INC.
    Inventors: Yoshimitsu Takakura, Naomi Oka
  • Patent number: 9540678
    Abstract: The present invention intends to provide an assay system using split luciferase that has a remarkably high detection sensitivity. In an embodiment, binding of mutually binding first and second proteins is detected by preparing a first fusion protein comprising the first protein fused with a peptide having the amino acid sequence of amino acid SEQ ID NO: 1 and a second fusion protein comprising the second protein fused with a peptide having an amino acid sequence selected from the group consisting of amino acid SEQ ID NOS: 2 to 6, and allowing the first fusion protein to bind with the second fusion protein to form a complex, and detecting luminescence emitted from the complex.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: January 10, 2017
    Assignees: The University of Tokyo, Toyo Boseki Kabushiki Kaisha, ProbeX Inc.
    Inventors: Takeaki Ozawa, Naomi Misawa, Kenji Miura, Tasuku Okamoto, Shigeaki Nishii, Kenji Masuda
  • Patent number: 9513288
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: December 6, 2016
    Assignees: The United States of America as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Patent number: 9511119
    Abstract: Preparations containing hepatocyte growth factor (HGF) and hyaluronic acid (HA) and methods of making and using same. The HGF and HA preparations can be prepared together in solution as an injectable fluid without gelatinization, or impregnated within a porous hydrophilic matrix material with, or without, cross-linking of the HA with the matrix material. The preparations can be used as a dermal filler or to generate and promote healing of cartilage, vertebral discs, connective tissues such as tendons and ligaments and bone in vivo.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignee: NuTech Spine, Inc.
    Inventor: Howard P. Walthall, Jr.
  • Patent number: 9487768
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: November 8, 2016
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9474293
    Abstract: Transgenic plants that express CIVPS or intein modified proteins, compositions of matter comprising them, products of diverse applications made from the transgenic plants, methods to construct the transgenic plants containing CIVPS or intein modified genes, methods to express CIVPS or intein modified proteins in plants, and methods of using the transgenic plants.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: October 25, 2016
    Assignee: Agrivida, Inc.
    Inventor: R. Michael Raab
  • Patent number: 9464285
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 11, 2016
    Assignee: FACTOR BIOSCIENCE INC.
    Inventors: Matthew Angel, Christopher Rohde
  • Patent number: 9393323
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: July 19, 2016
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Patent number: 9387192
    Abstract: The present invention relates to a combined preparation comprising at least one rocaglamide derivative and at least one apoptosis inducing agent, preferably from the group of substances comprising agents inducing the extrinsic apoptotic pathway, antiproliferative agents and agents which induce apoptosis in T-cells by activation induced cell death (AICD) for the treatment of cancer.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 12, 2016
    Assignee: DKFZ DEUTCHERS KREBSFORSCHUNGSZENTRUM
    Inventors: Min Li-Weber, Peter H. Krammer
  • Patent number: 9309501
    Abstract: Isolated DNA polymerase and the mutant DNA polymerases thereof are provided. The DNA polymerases have good thermostability.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: April 12, 2016
    Assignee: Industrial Technology Research Institute
    Inventors: Tseng-Huang Liu, Pei-Shin Jiang, Chih-Lung Lin, Su-Jan Lee, Chao-Hung Kao
  • Patent number: RE46572
    Abstract: The present invention relates to a plasma biomarker for diagnosing hepatocellular carcinoma (HCC), in particular to the discovery of a protein in plasma using 2-D fluorescence differential gel electrophoresis (2-D DIGE), immunoprecipitation and Nano-liquid chromatography mass spectrometry (Nano-LC-MS/MS) system that was unknown on the basis of conventional techniques. By demonstrating the presence of liver carboxylesterase 1 (hCE1) in human plasma and confirming that its secretion level is higher in patients with HCC than in healthy volunteers, this invention may be used as a screening method to diagnose HCC at an early stage.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: October 17, 2017
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young-Ki Paik, Keun Na